the Canadian industrial hemp conundrum

1. The Hemp Bioactives Conundrum –
A Simplified Solution
- Nutraceutical potential has been limited due to
perception that hemp bioactives may be regulated as
Schedule F drugs
- Generic nature of the science discourages
proprietary pharmaceutical commercialization
within pharma parameters due to generic
economics
- - Canadian Patent 2,921,553 describes the methods
to enable all components
- - Multiple sector-networked supply chains
maximize the value
- - Bioactive applications are embodied as
formulations in products
- - Developers are the hemp bioactives industry
innovators

2. The Hemp Bioactives Conundrum –
A Simplified Solution
• - The solution is to create a robust set of networked,
interdependent generic hemp based supply chains with
mass commercialization of affordable products
• - The solution is Innovation via Intellectual Property that
can be broadly licensed as opposed to
simple silos with isolated regulations which
discourage innovation and commercialization of
all silos in an interactive, integrated manner
• - The solution is a control tower operating system that
licenses compatible applications and capitalizes
on the economies of scale

3. Grow a healthy , clean crop and swath it

4. Bales are a better way to quickly preserve the crop and
extend harvest season without exposure to the elements.
Bales can store 15-20 percent moisture crop until combining

5. Patent Pending Harvesting system
preserves the crop integrity beginning in the field

6. Check the bales for moisture so the can be safely stored,
monitor them in storage for changes in temperature
and dry them to 9-12 % with a bale drier, if required

7. Assemble bales at storage and store at processing hubs
in preparation for drying , then combining

8. At some locations “in field” primary processing is done in the field,
when weather and time constraints permit

9. Similar to the Mcloed Harvest system , the crop comes to the
harvester to complete the combining

10. All non-grain waste and Straw is conveyed to a pile
and removed as required

11. Straw is burned if no fibre processor expresses interests,
alternatively the straw can be re-baled to run a bale dryer
to dry bales to a uniform moisture prior to combining

12. Harvested grain is not simply separated from the stalks….
aggressive threshing methods are the first milling step
to render the grain a non viable derivative
as an integral part of harvesting operations

13. At commercial scale large pieces of stalk are scalped out of grain
and the primary milled grain is remilled to a fine flour
suitable to be transformed
into secondary derivatives, or used as is

14. Milling creates a uniform, pure and consistent quality flour

15. Flour can be heat treated to dry pasteurize it

16. The Hemp Bioactives Conundrum – Enabling Development
- Government control has focused on tracking THC, a component
hemp is bred to have a very low level of while ignoring the
bioactive entourage
- Other cannabinoids and terpenes exist in biomass; regulations
stifle commercialization of these compounds due to lack of clarity
- Intellectual property innovated to fill this vacuum via utilization of
a loophole in regulation which allows biomass to be converted to
derivatives as a “bin run” raw material
- Once derivatives are created
only the THC limits are currently tracked
- Intellectual property can be licensed to allow governments to
collect excise taxes on any specific hemp bioactive (eg CBD) in
compliance with future laws and regulations
- Royalties allow the IP owners to place strategic
investments to fill the gaps
in areas they see as bottlenecks for hemp bioactives
industry expansion
- Patents can provide generic licensing opportunities
to ramp up the industry

17. The Hemp Bioactives Conundrum – Supply Chains
- Patented harvest method enables on farm production of
derivatives as a part of harvest
- Mechanical separations, solvent extractions, fractionations
create supply chains for custom-compounding raw materials
- - Terpenes, and cannabinoids, are listed in several food,
NHP and pharma schedules so derivatives are targeted to
appropriate applications which match uses to regulations
- - Intellectual Property controls and tracks supply more
effectively than centralized regulatory policing and
facilitates regulatory compliance
- - Pharmaceutical, nutraceutical, medical marijuana licensed
producers, unlicensed dispensaries and food processors all
have applications utilizing derivatives as feedstock

18. The Hemp Bioactives Conundrum – Supply Chains
• - Secondary derivatives include dietary fibre, protein
powder, oilseed granules, full bioactive nutraceutical flour,
residual bioactive food flours, oils with various bioactive
profiles, nutraceutical bioactive-rich protein powder and
utility flour concentrates
• - Tertiary derivatives include edibles with varied bioactive
profiles with food, nutraceutical and medical
applications, dermal preparations in cosmetics
and cosmeceuticals, highly refined bioactives concentrates
with various profiles for food, flavor, aroma,
supplement and medical formulations.

19. The Hemp Bioactives Conundrum – Supply Chains
• - A supply-chain patent tracks the bioactives disposition
when it gathers one royalty at the farm-gate and a
second royalty at the retailer (checksum of inventory).
• - Farmers, as growers, are paid a premium to manage crops
to maximize bioactive content
• - Contracting of farm supply as part of Intellectual Property
licensing guarantees supply chain players a continuing
supply of product profile-specific ingredients

20. All the separate cannabis supply chains
are beginning to meet to solve common concerns

21. Industrial hemp is trying to find its place
in the matrix of cannabis derived businesses

22. The Hemp Bioactives Conundrum – The Food Sector
- Current products include protein powder, edible oils ,
oilseed powders and granules
- Future products include
edibles with hemp bioactive content
cooking flours and oils with bioactive content
- Food categories include:
margarines, soda pop, candies, beverages,
baked goods, soups, cakes and pastries to name a few
Regulations have and will continue to set the allowable
bioactive parameters of the finished consumer goods
which are formulated with bioactive concentrates
and hemp derivatives

23. Commercial flours rich in CBD can find their way
into common food products

24. Beer wine , juice and soda pop flavored with hemp bioactives
fortify the nutritional value
of simple beverages
much as feeding flax to chickens produces omega 3 eggs.

25. The Hemp Bioactives Conundrum – The Nutraceutical Sector
- Concentrated derivatives and bioactives formulations in
powder and oil and tinctures can be used as starting
materials for single and compounded formulations including:
- dry capsules and tablets
- gel capsules
- dermal formulations
- flavorings
- compounded multi-component herbal products

26. Nutraceuticals present hempbioactivesto thefoodsupplement market. Theoneontheleft purports
to be somekindofmedicalmarijuanacontainingCBDwhenit actually onlycontains 40 PPM, whilethe
oneon therighthas6000 PPM CBDbutmakesnoclaimsforcontainingCBD. It is ironicthatblack
market productsclearly list theCBDcontent onlabeling moreaccuratelythannutraceuticals

27. Nutraceuticals or doggie treats complement the lineup

28. Concentrated tertiary derivative extracts
based on the chemistry of hemp flour
are now available

29. Industrial Hempleavesfarms at .5 to 2.8%CBD,
is processedto concentratetheCBDto yield fine flour with 7-10%CBD.
After extraction it yieldshempoil with 30-45%CBD

30. Cosmeceutical and pet nutraceuticals
are derived from hemp bioactive concentrates

31. SOME CANADIAN HEMP PRODUCTS Deliberately Mislead
consumers to associate HEMP WITH MARIJUANA…..
This understandably puts regulators on edge

32. Hemp contains
non-traditional
cannabinoids
Caryophyllene
is a cannabinoid found in
Hops, pepper, cloves and oregano
It is a fallacy that cannabinoids are
only found in cannabis
Flax fibre also contains CBD
https://www.degruyter.com/
downloadpdf/j/cmble.2012.17.issue-
3/s11658-012-0023-6/s11658-012-0023-
6.xml

33. Health benefits of Cannabinoid Family Members

34. The Hemp Bioactives Conundrum –
The Licenced Producer Sector
- Persons with prescriptions for medical marijuana require
marijuana formulations high in hemp bioactives
other than THC, especially:
- cannabidiol, minor cannabinoids including caryophyllene
and caryophyllene oxide
- bioactive terpenes including myrcene, linalool, alpha
pinene, humulene, limonene

35. The Hemp Bioactives Conundrum –
The Licenced Producer Sector
• - licensed producers can authorize and contract processing
by GMP, site-licensed pharma and nutraceutical
manufacturers to create products of pharmaceutical quality
suitable not only for DTC but also pharmacy dispensed
products, liquor and other specialty vendors and export to
USA and countries where CBD is an over-the-counter
compound.
• - licensed producers can purchase generic hemp derivatives
to include as base material for their cannabis products
• - licensed producers can focus on THC, and outsource CBD,
so as to maximize the productivity of indoor production
capacity and capital management

36. LicensedProducers havea full spectrumof THC andCBDprofiles
in bothdryand oil formulations

37. The Hemp Bioactives Conundrum –
The Pharmaceutical Sector
- Pharmaceutical companies globally researching
pharmaceutical formulations need a reliable source of raws
or contract manufactured ingredients
to proceed to commercial products
- In countries where CBD is not regulated as a drug, such as
Switzerland, pharma companies desire to receive hemp
bioactives and derivatives of all sorts.
- In the USA where CBD is widely marketed, it is likely a
market for products formulated by GMP, Site Licensed
Canadian facilities would meet with
no objections from Federal Regulators

38. USA and EU have a much more developed market
for CBD supplements with negligible THC content

39. 2010 Humanity+ futurist conference at Harvardis the firsttime healthspanandlifespanbecame associatedwith
hemp …. Hemphas great utilityin the multidisciplinaryapproachto transforming crisis and palliation driven
medicine to preventative, regenerativeandenhancementmedicine. I spoke onhealthinformation management
systems withhempas a side note. A niceicebreaker when having beers at an after-partywithscientists Maria
KonovalenkoandAubrey De Grey ….
https://www.fightaging.org/archives/2016/09/a-visual-introduction-to-sens-rejuvenation-research/
http://longevitycookbook.io/

40. The Hemp Bioactives Conundrum – The Dispensary Sector
- Although dispensaries may or may not be properly licensed
or regulated so are considered illegally operating
- They embody the provision within the Natural Health
Product regulations that exempts businesses who
manufacture custom compounded formulations
for customers on the orders of an
alternative health practitioner with or without
dispensation by a licensed compounding pharmacist
- Dispensaries also carry edibles and novel formulations from
which to use to formulate custom compounded products
-

41. The Hemp Bioactives Conundrum – The Dispensary Sector
• Dispensaries are within the hemp industry, the equivalent of
the farmers market in the commercial food industry,
so are an evolving sector. It is in the
best interests of regulators to use collaboration
instead of confrontation in assisting and working with
the dispensary sector as it matures into
a long term player that fits a niche of its own creation
• - The entire industry has watched the dispensaries and
learned what works, and what does not, from their
experiences

42. Dispensaries are the leading edge , evidenced by the way
they have reached out to hemp as a product

43. Hemp derivatives find their way into some very sophisticated
concentrates and dermal products

44. The Hemp Bioactives Conundrum – The Black Market Sector
- Currently all sorts of businesses procure amounts of hemp
from farmers and sell everything from dispensary products
to highly manufactured high concentration crystal high CBD
for domestic or export sale, as well as converting CBD from
hemp using acid, time and temperature into THC
products, without any regard for law or regulation
http://chemistry.mdma.ch/hiveboard/methods/000479001.html
https://csatc.org/pdf-Scientific-Research/Watanabe2007.pdf
- Patent holders working together with Health Canada and
CHTA would then back-track these supply chains and to bring
this production into legally-approved channels engaging in
regulated and approved transactions.

46. The Hemp Bioactives Conundrum – The Black Market Sector
• - Over the last 3 years, several CHTA-member hemp farmers
and processors have begun to supply the dispensary and
black market with substantial quantities of hemp bioactives
destined for the medical marijuana and recreational
markets.
• A hemp-industry-driven authorization to supply emerging
legal supply chains would remove the economic incentive
for diverting bioactives to unapproved applications
more effectively than the perceived punishments which
currently are not curbing these transactions.

47. The marijuana black market has developed
CBD based formulations

48. Black market consumer products have also
combined CBD into products

49. The Hemp Bioactives Conundrum –
The Health Canada Regulatory Statement
• The Industrial Hemp Regulations (IHR) establishes a framework for the
authorization of specific activities with industrial hemp. However, certain
activities with industrial hemp are not within the scope of the IHR and cannot be
authorized by an industrial hemp licence; these include the production of
derivatives, such as oil, from whole industrial hemp plants, including sprouts, or
the leaves, flowers or bracts of those plants, as per subsection 2(2) of the IHR
which states:
• (2) These Regulations do not apply to
• (a) the importation, exportation, sale or provision of whole industrial hemp
plants, including sprouts, or the leaves, flowers or bracts of those plants;
• (b) the importation, exportation, sale, provision or production of any derivative or
product made from whole industrial hemp plants, including sprouts, or the
leaves, flowers or bracts of those plants; or
• (c) the importation, exportation, sale or provision of any derivative of seed, viable
grain or non-viable cannabis seed, or product made from that derivative,

50. The Hemp Bioactives Conundrum –
The Health Canada Regulatory Statement
• Under the current framework of the IHR, the use of whole industrial
hemp plant parts (which includes sprouts, leaves, flowers or bracts of
those plants) is not authorized.
• Activities outside of the scope of the IHR are subject to the
prohibitions set out in Part I of the Controlled Drugs and Substances
Act unless otherwise authorized under the regulations.

51. The Hemp Bioactives Conundrum –
The Health Canada Regulatory Statement
• However, an existing regulatory regime and exemption under the
CDSA does allow for the cultivation of cannabis and the production of
cannabis oil by licensed producers. That regime is established in the
Access to Cannabis for Medical Purposes Regulations (ACMPR) and in
section 56 of the CDSA. Please contact the Office of Medical Cannabis
at OMC-BCM@hc-sc.gc.ca should you require more information.
Further, it is possible to produce a derivative made from whole
industrial hemp plants, including sprouts, leaves, flowers or bracts of
those plants with a section 9 licence under the Narcotic Control
Regulations. Please contact the Controlled Drugs Section at
controlled_drugs_office@hcsc. gc.ca for information on a section 9
licence application

52. The Hemp Bioactives Conundrum –
The Health Canada Compliant Solution

53. The Hemp Bioactives Conundrum – Patent Excerpts
• [0026]One of the problems which could be addressed in the right
circumstances with a method of this type is the notion that industrial hemp
bracts , leaves and stems when they occur separately are disallowed to be
processed or sold as hemp in an any form as they are classified as
"controlled substances"by government regulators. Grain is allowed to be
processed into a wide range of food derivatives with the only requirement
that it contain less than certain amounts of THC , starting with less than
.3% in the raw materials. In agriculture, grain is defined as anything
exceeding 50% or more of the principal grain and less than 50% of other
grains, chaff and other biomass materials. The novel idea is that if the grain
definition is applied to hemp that the result is that a mixture of hemp grain
and biomass either in "bin run" or milled into an inseparable mixture that
is not defined by regulators as a "controlled substance".This enables the
industry to access large quantities of raw materials from farmers in a
manner that is not prohibited by regulation.

54. The Hemp Bioactives Conundrum – patent excerpts
• [0006]One example of this type of a regulatory scenario in which it is
believed that an enhanced production method which would accommodate
these types of raw crop material or finished crop products regulatory
restrictions is the production of crops that have regulated active
ingredients, such as hemp. Over the last hundred years, hemp has evolved
from a widely available multi-use crop to a highly regulated poorly utilized
crop. This invention seeks to remove dysfunctionalityfrom the stateof the
art of commercial activity that centers on the non THC cannabinoid and
terpene bio-actives originating in the industrial hemp plant. Currently non-
THC cannabis terpenes and cannabinoids science cannot be
commercialized to the extent that consumers demand. Industrial hemp
cannabis bio-actives when not presented as drugs containing THC, present
as food, nutritional supplements, medicinal foods, natural health products,
cosmetics,animal supplements and such other categories that government
regulators choose to place them within.

55. The Hemp Bioactives Conundrum – patent excerpts
• [0007] A control tower production method could be developed that would
accomodate many of the issues associated with these types of complicated
agricultural production scenarios. A control tower production method is a
method of manufacture or production used in many different industries that
centers around controlling all of the key or critical control points in a
manufacturing process to guarantee process performance or product quality or
output. In the particular contextof hemp production, there are several supply
chain critical control points in an integrated field to consumer industrial hemp
cannabis bio-actives supply chain that could benefit from the application of a
control tower management methodology, including to minimize incursion by
government regulators into such activities. These critical control points include
supply contracts for the production and delivery of crop material, prescribed crop
management practices including harvesting methods, novel processing and
extraction methods and consumer/consumerrepresentative driven field to
consumer supply contracts. Management using these critical control points will
enable cannabinoid and terpene bioactive commercialization in foods AND non-
drug formulations within existing government regulations.

56. The Hemp Bioactives Conundrum – CBD in Hemp Products
• The original intent of the IHR was to prevent THC derived from
Industrial Hemp from entering the marijuana marketplace. Any
interpretation to the contrary is in error.
• There is no requirement for grain to be conditioned or cleaned prior
to milling. And grain with 50.1 percent of the named grain denotes
the description of the resulting flour. For 3 years, It entered the USA
as milled oilseed. It was tested for THC by Border Protection agents
and passed each time.

57. The Hemp Bioactives Conundrum – CBD in Hemp Products
• At the time of Combining anywhere between 1 and 20 percent
percent of stalk, and biomass from the crop , milled and damaged
hemp seeds, and weed seeds comprises what is taken to storage as
“bin run” grain. The quoted regulation applies to leaves and plant
material which the combine removes and is blown out onto the
ground behind the combine. The key way to determine the intent is
the use of the word retting. There is no reason to believe it means
that the grain must be conditioned or run through a grain cleaner
prior to storing in a grainary.

58. “Hemp for Horses” - 2007

59. “Hemp for Horses” - 2007

60. The Hemp Bioactives Conundrum – CBD in Hemp Products
• What is governed by IHR is outside the scope of the
CDSA. Therefor if CBD, which is controlled under
the CDSA, is part of a product controlled directly or
indirectly by the IHR, it is out of the scope of the
CDSA and thus, unless specifically exempted from
the IHR, is within its scope.
• An example of this is THC, which is governed under
the CDSA but exempted within certain specified
limits by the IHR. This makes hemp oil or
derivatives containing CBD controlled by the IHR.

61. The Hemp Bioactives Conundrum – CBD in Hemp Products
• When a Licensed Producer buys hemp oil from
those producing it under the IHR, the CBD content
is neither allowed nor disallowed so it can be
deemed as being part of a product produced under
the IHR and properly received by Licensed
Producers as hemp oil or derivative. Once
received by a Licensed Producer, then the rules
that govern operation of Licensed Producers apply
to hemp grain or derivatives. Those regulations
allow them to possess both CBD and THC, thus the
CBD is brought within the scope of these permitted
activities.

62. The Hemp Bioactives Conundrum – CBD in Hemp Products
• All hemp derivatives in Canada contain measurable
amounts of hemp bio-actives which do not occur in the
seed itself. These impurities which include
microscopic pieces of the whole plant or grain
impregnated with juices derived from herbaceous plant
parts during the process of combine harvesting are
transmitted into all known hemp derivatives. The
proof of this is that all hemp derivatives contain a
measurable amount of both THC and CBD which
originates not in the seed but in the whole plant.
• Let me also refer to a situation that speaks to trace
amounts of hemp plant parts in hemp derivatives. The
USA, at one time, had a zero tolerance for THC in hemp
derivatives and banned entry of these products for
importation into the USA. Canadian exporters
responded and the solution was to deem zero to not be
zero but a measurable number rounded down to zero.

63. The Hemp Bioactives Conundrum – CBD in Hemp Products
• If I were to interpret the words of the regulations as
stated all hemp products produced in Canada since
1999, namely every single pound of grain and
derivative, would be deemed outside the scope of the
IHR and thus not permissible by your definition of the
scope of the IHR. That would mean that the entire
Canadian industrial hemp industry as we know it today
would fall outside the scope of the IHR.
• In this case bin run grain may contain all sorts of
dockage which may find their way into derivatives.
There are no IHR provisions within the law or
regulations to address this situation as either
permitted or prohibited.

64. The Hemp Bioactives Conundrum – CBD in Hemp Products
• Within the IHR there are no specific references to
any crop production techniques which could
remove 100.0 % of the whole plant. Manitoba
Harvest, a large producer of hemp derivatives, has
published online statements that all of their hemp
products contain measurable traces of whole plant
parts (CBD) … but they state also that the exact
amounts of the CBD marker compound in their
products are known to them, but will not be made
public.

65. The Hemp Bioactives Conundrum – CBD in Hemp Products
• The IHR does not specify that the grower, who also
converts grain to oil or meal or flour, must remove any
impurities from bin run grain unless HC has approved
that grower to be licensed as a conditioner. For 17
years HC has licensed both growing as well as creation
of derivatives on one license. HC issues licenses for
farmers to convert grain to derivatives without
requiring them also to be licensed as conditioners, or
use the services of conditioners or even set
permissable levels of residual materials ; therefor, it
can be reasonably expected that bin run grain could be
used as the input grain material for all Canadian
farmers.

66. The Hemp Bioactives Conundrum – CBD in Hemp Products
• Nowhere in the regulations does it state that grain
must be conditioned, nor what the standards for
conditioned grain must be prior to conversion into
derivatives.
• There has been a misinterpretation by the IHR as
to the terminology defining impurities in hemp e.g.
plant part terms. CBD as a reliable chemical
fingerprints of the presence of hemp plant parts in
all hemp derivatives … indicating that all known
hemp grain derivatives contain miniscule amounts
of whole hemp plant parts.

67. The Hemp Bioactives Conundrum – CBD in Hemp Products
• The intent of the regulatory scope of the IHR may
not apply to the whole plant nor its named parts
nor does it place limits on the incidental content of
these in derivatives exists except controlling for
the THC limits which are derived from plant part
content. The regulations place no specifications
as to incidental minor inclusions into hemp grain as
far as content of any other bioactive. All Hemp
derivatives contain other bio-actives of which CBD
is a good indicator of the presence of whole plant
parts or the residue thereof.

68. CBD in hemp products is detailed in peer reviewed papers
• Cannabis sativa L. in Foodstuffs: the Italian Case and
the Need for
• EU Harmonised Limits for THC Unavoidable
Contamination
• Sabino A. Bufo, Simone Milan, Luigi Milella, Laura
Scrano and Cesare Varallo*
• Reports European Food & Feed Law Review 1|2016
pgs 52-57
• “Cannabis seeds have been extensively described in
the scientific literature, and some traces of
cannabinoids has been occasionally found in seed-
derived oils, mainly due to external contaminants such
as resin adherent to the seed or plant parts’ residues”

69. CBD in hemp products is detailed in peer reviewed papers
• The Composition of Hemp Seed Oil and Its Potential as an
Important Source of Nutrition
• Cary Leizer, David Ribnicky, Alexander Poulev, Slavik
Dushenkov, Ilya Raskin
• Journal of Nutraceuticals, Functional & Medical Foods Vol.
2(4) 2000
• 2000 by The Haworth Press, Inc. All rights reserved. Pg 35-
53
• “Although previously identified only in the essential oils of
the Cannabis plant (Hendriks et al., 1978), terpenoid
compounds have been identified as being present within the
seed oil. Health benefits may be gained from their presence
even at concentrations similar to that of CBD. As is the case
with CBD, the presence of these terpenes is most likely the
result of contamination from glandular hairs during oil
processing.

70. CBD in hemp products is detailed in peer reviewed papers
• “The cultivation of modern day industrial hemp
crops in more northern latitudes will show a gross
chemotype of high CBD/low THC. With these
‘‘unripe’’ varieties, it will be possible to take
advantage of the relatively high levels of CBD as
compared to THC, and exploit the many benefits of
CBD without risk of psychoactivity. The oil which
was subjected to investigation here was Canadian
grown. It has significant concentrations of CBD but
no detectable THC. These results are consistent
with the predicted cannabinoid content of
northern-grown plants.”

71. The Hemp Bioactives Conundrum – CBD in Hemp Products
• To clarify, the 46 page document entitled "Control
Tower Production Method for Crop Fractions and
Derivatives" , patent 2, 902, 766 :
• Put simply , when hemp is grown , processed and
marketed as described in my patent and demonstrated
in this presentation it is covered by my patent and is
compliant with the Industrial Hemp Regulations. Thus
all CBD found in the resulting derivatives as is already
the case with all hemp derivatives on the market are to
be treated equally as not within the scope of the CDSA
and wholly within the scope of the Industrial Hemp
Regulations

72. The Hemp Bioactives Conundrum – Complementary Strategies
-Legal challenges based on Class Action Lawsuits and anti “Regulatory
Racketeering” statutes using “Power of Dominance” with malice.
-Can be filed on behalf of Growers, Primary Processors, Licensed
Producers, Dispensaries , and owners of Intellectual Property
representing the damaged parties seeking monetary compensation
for amounts estimated in the double digit billions CAD.
-Intentional regulatory changes which impoverish
any or all of the above parties to several supply chains
would be stayed or reversed as a result.
-Additionally, Charter challenge is also an option. This has a history of
success having gone to the supreme court and ordered satisfactory
fixes for non monetary recourse.

73. http://www.channelingreality.com/Power/regulatory_racketeer
ing.htm

74. The Hemp Bioactives Conundrum –
Summary : 15 November 2016
“There is a globally emerging healthspan and lifespan is the target-market. This
developing market can grow what is a 2,000 acre biomass acreage in 2016 to about
20,000 acres in 2018 and a million acres by 2022. The economic benefit to both public
and medicare is obviously significant.
1 cent a milligram CBD in multiple formulations, if delivered at a consolidated daily
dose of 100 mg a day as a dietary supplement for 25 million people, would require
912.5 billion mg. At 100 kg/acre of 1% CBD hemp it would take require 912,500 acres
of Industrial Hemp.
Canada, with a default public medicare system, has the moral hazard that health-
supporting ingredients which are not fully commercialized in a timely fashion cost
medicare and the taxpayer for avoidable Crisis Management and Palliative Care
resource allocations. “
Governments do not need to tax CBD as the benefits will accrue directly to the
population and allow reallocation of savings in scarce medicare resources to new
regenerative and enhancement technologies.
Morris Johnson holds title to the aforementioned IP and is the author of this presentation.
Morris Johnson / Lifespan Pharma Inc.
24-1035 Boychuk Drive, Saskatoon, Sask., S7H-5B2
1-306-716-7822
Lifespan.pharma.inc@gmail.com

75. REBRAND CANADIAN HEMP AS AN ANTI- AGING INGREDIENT

76. Hemp has an identity crisis in the minds of many today